Ilaria Motta
Turin, 10149, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment.
Journal: Nature communications
Published: February 05, 2026
Response to the Union's statement on ongoing conflicts and impact on health services.
Journal: IJTLD open
Published: January 21, 2026
Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients.
Journal: Scientific reports
Published: December 07, 2025
The time is now: making the case for compassionate use/pre-approval access to new TB drugs.
Journal: IJTLD open
Published: October 03, 2025
Clinical best practices for caring for people with expanded resistance to newer TB drugs.
Journal: IJTLD open
Published: April 06, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: March 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Journal: The New England journal of medicine
Published: January 29, 2025
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Journal: Antimicrobial agents and chemotherapy
Published: June 06, 2024
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation.
Journal: The Lancet. Global health
Published: January 05, 2024
Standards for clinical trials for treating TB.
Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: December 02, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Journal: The Lancet. Respiratory medicine
Published: September 01, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 19, 2023
Last Updated: 09/26/2026